ESR1 and breast carcinoma: A total of 354 consecutive LB samples from breast cancer patients progressing on ET analyzed with the HS2-Mamma-LIQ NGS assay revealed 154 samples (43%) with an alteration in the ESR1 LBD, and 145 samples (41%) were found to have at least one ESR1 hotspot mutation (Figure 3).